Hepatitis A: A Traveling Target

Andersson, Karin L.

doi:10.1001/archinternmed.2010.412

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in this age of international travel, an increasing number of adults travel to areas endemic for hepatitis A and B, thus increasing the risk of infection [Zuckerman and Hoet, 2008;Askling et al, 2009]. A recent report showed that in the United States, universal mass vaccination with hepatitis A vaccine has drastically reduced the incidence of hepatitis A; and the majority of recent hepatitis A cases and outbreaks have been attributed to international travelers to areas endemic for hepatitis A and immigrants [Andersson and Friedman, 2010]. Similar observations indicating a negative correlation between universal mass immunization against hepatitis A and HAV-associated morbidity have been reported in other countries [Andre, 2006;Torner et al, 2011].…”

Section: Discussionmentioning

confidence: 99%

Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine

Damme¹,

Leroux‐Roels

Crasta

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

A combined hepatitis A and B vaccine is available since 1996. Two separate open-label primary studies evaluated the immunogenicity and safety of this hepatitis A and B vaccine (720 EI.U of HAV and 20 µg of HBsAg) in 306 healthy subjects aged 17-43 years who received three doses of the vaccine following a 0, 1, and 6 months schedule. These subjects were followed up annually for the next 15 years to evaluate long-term persistence of anti-HAV and anti-HBs antibodies. The subjects whose antibody concentrations fell below the cut-offs between Year 11 and Year 15 (anti-HAV: <15 mIU/ml; anti-HBs: <10 mIU/ml) were offered an additional dose of the appropriate monovalent hepatitis A and/or B vaccine. In subjects who received the additional vaccine dose, a blood sample was collected 1 month after vaccination. At the Year 15 time point, all subjects in Study A and Study B were seropositive for anti-HAV antibodies and 89.3% and 92.9% of subjects in the respective studies had anti-HBs antibody concentrations ≥10 mIU/ml. Four subjects (two in each study) received an additional dose of monovalent hepatitis B vaccine and mounted anamnestic responses to vaccination. No vaccine-related serious adverse events were reported. This study confirms the long-term immunogenicity of the three-dose regimen of the combined hepatitis A and B vaccine, as eliciting long-term persistence of antibodies and immune memory against hepatitis A and B for up to at least 15 years after a primary vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine

Damme¹,

Leroux‐Roels

Crasta

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…1 The adult population is increasingly at risk of contracting HAV infection as they remain susceptible for a longer duration and are increasingly exposed to the virus by traveling to HAV endemic regions. 2,3 As a consequence, HAV, so far thought to be a benign, mostly self-limiting and rarely fatal disease, 1 will become more symptomatic as pathology worsens with adult age.…”

Section: Introductionmentioning

confidence: 99%

Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine

Herck¹,

Crasta

Messier

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background and objectives: Antibody persistence and immune memory against hepatitis A (HAV) in adults in a low endemicity country, 15 y after immunization with two doses of HAV vaccine has been demonstrated. This communication provides additional information on antibody persistence up to Year 17 from two of the longest follow-up studies [NCT00289757/NCT00291876].Methods: In two double-blind primary studies, healthy adults aged 17240 y and 21240 y, respectively received two doses of the HAV vaccine following a 0,6 mo or 0,12 mo schedule. Anti-HAV antibody concentrations were measured using an enzyme-linked immunoassay (cut-off: 15 mIU/ml) at Year 16 and Year 17. Subjects who became seronegative (anti-HAV , 15 mIU/ml) since previous reporting were offered a challenge dose, with anti-HAV antibody concentration measurements at Day 14 and Day 30 thereafter.Results: At Year 17, 100% and 96.7% of subjects remained seropositive for anti-HAV antibodies following the 0, 6 mo and 0, 12 mo regimens, respectively (GMCs: 278 mIU/ml and 369 mIU/ml). One subject who became seronegative at Year 16 received a HAV challenge dose within the next 12 mo and mounted an anamnestic response. The challenge dose was well-tolerated.Conclusions: Both HAV immunization regimens (0,6 mo and 0,12 mo) induced persistence of vaccine-induced antibodies against HAV for at least 17 y after primary vaccination.

show abstract

Hepatitis A: A Traveling Target

Cited by 2 publications

References 8 publications

Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine

Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine

Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine

Contact Info

Product

Resources

About